How We WorkOrder NowSupport Privacy

Biotechnology Industry Volume Giants of Friday: (NYSEAMEX:HEB), (NASDAQ:ARNA), (NASDAQ:HALO), (NASDAQ:ARRY)

on 24/12/2012

Houston, TX –December 24, 2012 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

Today’s focus is on: HEB, ARNA, HALO, ARRY

Hemispherx BioPharma, Inc (NYSEAMEX:HEB) started the trading session at $0.28 and to closed at $0.280, by moving down -22.22%. The beta of the stock remained 1.29. HEB gained awesome volume of 11.32 million shares on Friday.

Here is a view of some earlier trends of HEB: The 1 month performance was down and the stock fell -62.67%, while the 6 months performance was also negative -5.88%, YTD performance showed it a gainer of +43.52%.

Is HEB A Solid Investment At These Levels? Find Out Exactly Where HEB Is Headed With This TREND ANALYSIS REPORT

The second stock among the volume gainers of the Biotechnology Industry was Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), as it traded with volume of 11.32 million shares, compared to its average volume of 4.72 million shares, average trading capacity was startlingly lower.

In Friday’s trading session, the stock plunged -22.22%, while tracking its 5 days performance, it also showed a bearish trend of -59.12%.

Get A Free Report And Detailed Analysis On ARNA CLICK HERE To Read

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was in the stream of heavy volume Biotechnology stocks, as its trading volume of Friday’s trading activity was 9,014,600 shares. The average volume of the stock remained 910,288 shares.

The 52 week price range of the stock remained $3.86 – $13.50 and its day range was $6.21 – $7.19. The stock showed an increase of +26.99% to close the session at $7.01.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has updated that the company has signed an international Collaboration and License contract with PFE for the intention of develpoing and commercializing products combining proprietary PFE biologics with HALO ‘s Enhanze™ technology.

How Should Investors React To HALO Now? Find Out In This TREND ANALYSIS REPORT

Array Biopharma Inc (NASDAQ:ARRY), traded with strong volume of 8,950,600 shares and its average volume was 1.86 million shares.

The stock gained the sturdy volume but, the percentage change showed that ARRY fell -0.83% in the most recent trading session.

The stock showed weekly, monthly and quarterly performances of -2.45%, +3.47% and -37.52%, respectively. Institutional Ownership remained 64.84%.

How Should Investors Trade ARRY Now? Don’t Trade ARRY Until You Read This TREND ANALYSIS REPORT

Disclaimer:

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

 

Source: anotherwinningtrade Posted Mon, December 24, 2012 14:19 - Permalink